title: The shadow of inequitable conduct in the US patent application.
abstract: Inequitable conduct regarding any single claim can render the entire patent unenforceable and further damage other related patents and applications in the assignee's patent portfolio. The adverse impact of inequitable conduct significantly became a litigation strategy. The US Federal Circuit (CAFC) observed that inequitable conduct as a patent litigation strategy had become a plague and thus tightened the standard for finding inequitable conduct in a case with full court judges. However, under the shadow of previous adverse impact of inequitable conduct, patent applicants may still submit many marginal related references. This study demonstrates that an applicant even prepared an information disclosure statement (IDS) as many as 50 pages. Actually, under the new standard, inequitable conduct would not further produce significant impact in the US patent system. Thus, a patent applicant need not submit marginal references but should distinguish the prior art from the current application, especially for those listed in the IDS, to avoid the novelty rejection.
authors.affiliation: a Rehabilitation Center, Taipei Veterans General Hospital , Taipei , Taiwan.
authors.forename: Bao-Chi
authors.initials: BC
authors.lastname: Chang
authors.affiliation: b Division of Experimental Surgery , Department of Surgery, Taipei Veterans General Hospital , Taipei , Taiwan.|c Institute of Hospital and Health Care Administration and Institute, National Yang-Ming University , Taipei , Taiwan.
authors.forename: Shyh-Jen
authors.initials: SJ
authors.lastname: Wang
mesh_terms: D030881:Disclosure / Q000941:ethics / Q000331:legislation & jurisprudence*; D007603:Jurisprudence; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D014481:United States
keywords: inequitable conduct; information disclosure statement; intent; materiality; patent portfolio
references.citation: Expert Rev Anticancer Ther. 2014 Dec;14(12):1477-93
references.pmid: 25138900
references.citation: Hum Vaccin. 2011 May;7(5):569-73
references.pmid: 21552000
references.citation: Nat Biotechnol. 2013 Jun;31(6):501-3
references.pmid: 23752433
references.citation: Nat Biotechnol. 2009 Dec;27(12):1125-6
references.pmid: 20010590
references.citation: Hum Vaccin Immunother. 2012 Oct;8(10):1443-9
references.pmid: 22894949
references.citation: Hum Vaccin. 2011 Apr;7(4):474-6
references.pmid: 21808149